Deadline for Receipt of Abstracts has been extended to:
Friday, February 5, 2010, 5:00 p.m. EST

Deadline for Late Breaking Research Abstracts:
Monday, February 15, 2010

For a Call for Abstracts form, click here...

Presented by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group, Myoclonus Study Group, Tourette Syndrome Study Group, Cooperative Ataxia Group, and Tremor Research Group

The Symposium will consist of current issues in genetic and environmental contributions to Parkinson's disease and other movement disorders with peer-reviewed platform and poster presentations designed to communicate recent research advances, including new pharmacological and non-pharmacological treatment options, in the field of Parkinson’s disease, Huntington’s disease, ataxia, dystonia, myoclonus, Tourette’s syndrome, tremor and other movement disorders thereby enhancing patient care. Professionals in neurology and related disciplines as well as practitioners, psychologists, educators, and researchers are invited to attend.  The gaps in clinical practice we wish to address are the unmet needs pertaining to the translational and clinical evaluation, along with the care and treatment of patients and families affected by PD and other movement disorders.

Abstracts of platform and poster presentations representing original material will be published in the April 2010 issue of Movement Disorders.

At the conclusion of this session, participants should be able to: 1) To understand the rationale for the major approaches to investigating the genetic causes of human disease; 2) To review the current state of knowledge regarding genetic contributions to PD and other movement disorders; 3) To understand the evidence for environmental contributions to the cause of PD and other movement disorders; 4) Identify and describe by scholarly review, oral presentation and group discussion the current research into the diagnosis and treatment of Parkinson’s disease (PD) and other movement disorders which may be relevant to current treatment or which may lead to the development of further research protocols; 5) Distinguish and assess the important advances in research and clinical treatments relating to a Parkinson's disease and other movement disorders in terms of available treatment options or new methodologies for clinical research; 6) Explain new pharmacological and non-pharmacological treatment options available for Parkinson’s disease and other movement disorders in connection with their clinical practice or with regard to further clinical research methods; 7) Interpret the mechanisms (genetic, environmental, pathophysiology, neurobiology) linked to Parkinson’s disease and other movement disorders when assessing Parkinson's disease or other movement disorder patients or when developing new research protocols; and 8) Employ diagnostic approaches and tools available for assessing Parkinson’s disease and other movement disorders when diagnosing new patients or when conducting clinical research.

Please contact Roseanna Battista at roseanna.battista@ctcc.rochester.edu with any questions.

PSG OVERVIEW | PARKINSON'S DISEASE OVERVIEW | WHAT IS A CLINICAL TRIAL

CLINICAL TRIALS IN PROGRESS

COMPLETED CLINICAL TRIALS | PSG / MDS SYMPOSIA | PUBLICATIONS / ABSTRACTS

CONTRIBUTIONS | OTHER USEFUL LINKS